CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：The multiple facets of ovarian high grade serous carcinoma: A review on morphological, immunohistochemical and molecular features.
The multiple facets of ovarian high grade serous carcinoma: A review on morphological, immunohistochemical and molecular features.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
高级别浆液性卵巢癌（HGSOC）是上皮性卵巢癌中最具侵袭性的亚型，也是妇科恶性肿瘤死亡的主要原因。本综述旨在全面分析HGSOC的形态学、免疫组化和分子特征，重点阐述其发病机制，并识别具有诊断、预后和治疗意义的生物标志物。特别关注肿瘤微环境（TME）和基因组不稳定性在塑造肿瘤行为及治疗脆弱性中的作用。讨论了关键进展，如TP53和BRCA突变的识别、同源重组修复（HRR）缺陷的分类，以及叶酸受体α（FRα）和PD-L1等生物标志物的临床意义。这些发现揭示了对靶向治疗的可操作见解，包括免疫检查点抑制剂和PARP抑制剂，这些治疗有望改善HGSOC的预后。本综述旨在弥合对HGSOC多层面生物学理解上的差距，增强临床决策，并促进精准治疗的发展。
High-grade serous ovarian carcinoma (HGSOC) is the most aggressive subtype of epithelial ovarian cancer and a leading cause of mortality among gynecologic malignancies. This review aims to comprehensively analyze the morphological, immunohistochemical, and molecular features of HGSOC, highlighting its pathogenesis and identifying biomarkers with diagnostic, prognostic, and therapeutic significance.
Special emphasis is placed on the role of tumor microenvironment (TME) and genomic instability in shaping the tumor's behavior and therapeutic vulnerabilities. Key advancements, such as the identification of TP53 and BRCA mutations, the classification of homologous recombination repair (HRR) deficiencies, and the clinical implications of biomarkers like folate receptor alpha (FRα) and PD-L1 are discussed.
These findings reveal actionable insights into targeted therapies, including immune checkpoint inhibitors and PARP inhibitors, which hold promise for improving outcomes in HGSOC. This synthesis of knowledge aims to bridge gaps in understanding HGSOC's multifaceted biology, enhance clinical decision-making, and foster the development of precision therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
